Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer

Can-Fite BioPharma Ltd CANF provided an update on its clinical program for Namodenoson for hepatocellular carcinoma (HCC).
At two upcoming conferences, Can-Fite will present the latest data comparing the response of liver cancer patients to those with HCC Child-Pugh B (CPB) and share the latest findings on a CPB liver cancer patient who remains cancer-free six years after she began treatment with Namodenoson.
Can-Fite's prior Phase 2 study showed that median overall survival in the CPB7 patient population was 6.8 months for those treated with Namodenoson compared to 4.3 months for those treated with a placebo.
The < 1-year survival in the whole patient population was 32% in the namodenoson-treated group vs. 14% in the placebo-treated patients. In the CPB7 population, 44% survival was found in the namodenoson-treated group vs. 18% in the placebo-treated one.
A pivotal Phase 3 registration study is open for enrollment of the most advanced liver cancer patients.
The trial will enroll 450 patients diagnosed with HCC and underlying CPB7.
Price Action: CANF shares are up 13.3% at $0.68 on the last check Wednesday.